论文部分内容阅读
目的探讨孟鲁司特钠联合沙美特罗替卡松治疗儿童咳嗽变异性哮喘(CVA)的临床效果。方法回顾性分析2011年1月至2014年1月CVA患儿118例的临床资料,其中61例给予孟鲁司特钠及沙美特罗替卡松治疗为观察组,另57例给予沙美特罗替卡松为对照组,比较两组咳嗽缓解、消失时间及治疗总有效率、复发率。结果观察组临床总有效率(93.4%)优于对照组(80.7%),观察组咳嗽缓解及消失时间短于对照组,差异均有统计学意义(P<0.05)。停药后随访8~12个月,观察组复发率(3.28%)低于对照组(17.54%),差异有统计学意义(P<0.05)。结论孟鲁司特钠联合沙美特罗替卡松治疗CVA效果好,复发率低,值得临床推广应用。
Objective To investigate the clinical efficacy of montelukast sodium combined with salmeterol and fluticasone in the treatment of children with cough variant asthma (CVA). Methods The clinical data of 118 children with CVA between January 2011 and January 2014 were retrospectively analyzed. Among them, 61 patients were treated with montelukast sodium and salmeterramide, and the other 57 patients were given salmeterol Ticase for the control group, compared the two groups cough relief, disappearance of time and treatment of the total efficiency, recurrence rate. Results The total clinical effective rate (93.4%) in the observation group was better than that in the control group (80.7%). The relief and disappearance of cough in the observation group were shorter than those in the control group (P <0.05). The patients were followed up for 8 to 12 months after stopping the treatment. The recurrence rate in the observation group (3.28%) was lower than that in the control group (17.54%), the difference was statistically significant (P <0.05). Conclusion Montelukast combined with salmeterol and fluticasone in the treatment of CVA has a good effect and a low recurrence rate, which is worthy of clinical application.